Evercore ISI Shines Some Light on Rocket Pharmaceuticals (RCKT) Regulatory Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. GNK
3. NVDA
4. AZN
5. SPCX
6. FNGR
7. PLUR
8. EYPT
9. HIVE
10. GSAT

Go back to Evercore ISI Shines Some Light on Rocket Pharmaceuticals (RCKT) Regulatory Update

BTIG Reiterates Buy Rating on Rocket Pharmaceuticals (RCKT), Defending on Weakness

December 22, 2022 1:51 PM EST

BTIG analyst Yun Zhong reiterated a Buy rating and $35.00 price target on Rocket Pharmaceuticals (NASDAQ: RCKT).

The analyst comments "We believe the confirmation of a single-dose, open-label study, using natural history data as a comparator, as the pivotal study design should be a win for Rocket. The FDA's openness to considering a biomarker-based composite endpoint is encouraging, although a definitive agreement on an accelerated approval pathway relying on specific... More

Cowen Defending Rocket Pharmaceuticals (RCKT); 'shares should be up on this'

December 22, 2022 11:47 AM EST

Cowen analyst Tyler Van Buren reiterated an Outperform rating on Rocket Pharmaceuticals (NASDAQ: RCKT)

The analyst comments "We caught up with mgmt after this morning's release, and they sound much better than the legal jargon ("openness"; "continued dialogue") in the release implies.... More

Rocket Pharmaceuticals (RCKT) Provides Update on Anticipated Registration Path for RP-A501

December 22, 2022 6:01 AM EST

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces updates from the Company's end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding RP-A501, the Company's investigational... More